Vaccine biotechnology company Novavax (NASDAQ: NVAX) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 3% year on year to $68.3 million. The company’s full-year revenue guidance of $400 million at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP loss of $0.19 per share was 54.8% above analysts’ consensus estimates.

Is now the time to buy NVAX? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Novavax’s third quarter results were marked by a notable revenue outperformance versus Wall Street expectations, with management attributing this primarily to a one-time $125 million milestone from Sanofi’s phase III influenza/COVID-19 combination vaccine trial. Despite this, overall sales declined year over year, and the market responded negatively. CEO John Jacobs cited the company’s ongoing efforts to drive targeted research and development while maintaining a lean operating model as key factors. Management also acknowledged that reduced R&D reimbursements and cost reductions contributed to improved operating margins compared to last year.

Looking ahead, Novavax’s guidance for the remainder of the year is supported by anticipated milestone payments from Sanofi, ongoing collaborations with partners such as Pfizer and Takeda, and the development of its C. difficile vaccine candidate. Management emphasized that future performance hinges on expanding the use of its Matrix-M adjuvant platform and progressing early-stage oncology projects. CFO Jim Kelly highlighted the company’s commitment to further cost reductions, stating, “We expect to reduce our non-GAAP R&D and SG&A expenses by over $200 million by 2028,” as Novavax aims to achieve non-GAAP profitability tied to the successful commercial launch of partner products.

Key insights from management’s remarks

Management attributed performance to milestone revenue from partnerships, progress in pipeline development, and substantial cost reductions as they shift toward a capital-efficient business model.

• Sanofi milestone payment: Novavax received a $125 million milestone after Sanofi initiated a phase III trial for a combination influenza/COVID-19 vaccine, reflecting successful execution of strategic partnerships and adding a substantial non-recurring boost to quarterly revenue.
• Matrix-M adjuvant demand: There was robust demand for Novavax’s Matrix-M adjuvant technology from partners for use in both commercial and development-stage vaccines, with management emphasizing that this demand led to higher supply sales in the quarter.
• Nuvaxovid commercial efforts: Sanofi and Takeda expanded promotional activities for Nuvaxovid, the company’s COVID-19 vaccine, including targeted campaigns in the U.S. and Japan. Management noted that these efforts resulted in increased vaccine uptake and set the stage for greater market awareness in subsequent seasons.
• R&D expense reductions: Novavax achieved a 41% reduction in GAAP R&D and SG&A expenses year over year, aligning with management’s goal to maintain a lean and agile operating model. This included headcount and operating footprint reductions.
• Pipeline diversification: The company advanced its C. difficile vaccine candidate toward clinical trials and initiated exploratory oncology studies, aiming to leverage its technology across infectious disease and cancer applications.

Drivers of future performance

Management’s outlook is underpinned by milestone revenue from partnerships, expansion of the Matrix-M platform, and disciplined spending.

• Reliance on partner milestones: The company’s forward guidance assumes continued milestone payments from existing partners, particularly Sanofi, with the timing of U.S. regulatory approvals for combination vaccines being a critical variable for revenue and profitability.
• Pipeline and platform expansion: Novavax expects future growth to be driven by advancing its C. difficile vaccine candidate into clinical development and by generating new data on Matrix-M, both for infectious disease and early-stage oncology indications. Management noted that the breadth of data generated is intended to support additional partnership opportunities.
• Continued cost discipline: Plans to further reduce R&D and SG&A spending, including operating footprint consolidation and headcount reductions, remain a focus. Management indicated that reaching non-GAAP profitability by 2029 is dependent on these efforts as well as successful product launches by partners.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) progress on Sanofi’s phase III combination vaccine trials and anticipated U.S. regulatory developments, (2) the timeline and data readouts for Novavax’s C. difficile vaccine candidate moving into clinical studies, and (3) evidence of sustained demand for Matrix-M adjuvant technology in both commercial and development-stage partnerships. Updates on cost containment measures and new collaborations could also be important signposts for execution.

Novavax currently trades at $9.84, down from $10.67 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High quality stocks for all market conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.